NCT01817452View on ClinicalTrials.gov

A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol

PHASE2CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

January 15, 2025

Study Completion Date

January 15, 2025

Conditions
Breast Cancer
Interventions
DRUG

Trastuzumab

DRUG

Pertuzumab

DRUG

Paclitaxel

Trial Locations (1)

41061

Ev. Krankenhaus Bethesda Brustzentrum Niederrhien, Mönchengladbach

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

West German Study Group

OTHER

NCT01817452 - A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol | Biotech Hunter | Biotech Hunter